Rob advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including ’34 Act and public company reporting, corporate governance, and stock exchange rules.

Rob regularly helps clients strategize capital raising efforts, navigate risk, and tell a story through filings and disclosures over the long term. He represented Loxo Oncology in its IPO, follow-on offerings and its $8 billion acquisition by Eli Lilly and DICE Therapeutics in its IPO, follow-on offerings and $2.4 billion sale to Eli Lilly. He also represented DexCom, Day One Biopharmaceuticals, Morphic Holding, Prelude Therapeutics, and Third Harmonic Bio in their respective IPOs and subsequent follow-on offerings. Rob is committed to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA, Chambers Global and Legal 500, and a preeminent life sciences practitioner by LMG Life Sciences, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chaired Practising Law Institute’s How to Prepare an Initial Public Offering annual program for several years.